Mechanisms of Pathological Cardiac Remodeling and Heart Failure

This direction is merged into another direction: pathological cardiac hypertrophy. Its last version stays readable and citable here.

Version 1 of 129 papers34 conceptsfrozen 2026-10-04

When the heart faces chronic stress—whether from high blood pressure, lung disease, or metabolic dysfunction—it does not simply fail overnight. Instead, it undergoes a complex structural transformation known as cardiac remodeling. This process is a double-edged sword: it begins as a necessary adaptation to maintain circulation but often spirals into a self-reinforcing cycle of stiffening, scarring, and eventual pump failure.

The Geometry of Compensation

The heart’s primary goal is to maintain cardiac output against resistance (afterload). According to the Law of Laplace, as the pressure inside a chamber increases, the stress on the chamber wall rises. To normalize this stress, the heart muscle cells (cardiomyocytes) grow larger, thickening the walls. This "concentric hypertrophy" is initially beneficial.

As Fen Ai and colleagues note, this thickening helps the heart handle the "pressure overload" of hypertension. However, this growth is not infinite. Xiaoliang Han describes how molecular triggers, such as the long non-coding RNA SLC26A4-AS1, can push this growth beyond healthy limits. When the walls become too thick, the heart loses its "compliance"—its ability to stretch and fill with blood during the resting phase (diastole). JinYan Tong demonstrates that in dialysis patients, this structural thickening is the primary predictor of diastolic dysfunction.

The Maladaptive Transition

The transition from "adaptive" to "pathological" remodeling is marked by two major changes: fibrosis and dilation.

  1. Fibrosis: Instead of just muscle growth, the heart begins to deposit excess connective tissue (collagen). This "scarring" makes the heart stiff. Ping Wang identifies the transcription factor FOXO3A as a potential protector against this scarring, while Abdullah Hamad shows that enhancing adenosine receptor signaling can arrest this structural decline.
  2. Dilation: Eventually, the thickened walls can no longer sustain the pressure. The heart chambers begin to stretch and thin out, changing from a streamlined "almond" shape to a spherical "balloon" shape. Francesca Coppi explains that this spherical expansion is far less efficient at displacing blood than the original geometry, leading to a drop in pumping efficiency.

The Unique Burden of the Right Ventricle

While much research focuses on the left ventricle (the body's main pump), the right ventricle (RV) faces unique challenges in conditions like Pulmonary Arterial Hypertension (PAH). In PAH, the arteries in the lungs become stiff and narrow, forcing the RV to pump against massive resistance.

M. Umar Qureshi uses fluid dynamics modeling to show that this isn't just about mean pressure; increased arterial stiffness creates "wave reflections" that bounce back and hit the heart, further straining the RV. Benjamin Orkild found that regardless of the cause, a failing RV eventually adopts a predictable, distorted 3D shape, which serves as a visual marker that the heart's compensatory mechanisms have failed.

Interestingly, the heart shows remarkable plasticity. Xu Chen observed that people migrating to high altitudes initially suffer RV impairment, but over several years, the heart undergoes a "biphasic" response where it successfully remodels itself to regain function despite the low-oxygen environment.

Molecular Brakes and New Therapies

If remodeling is a runaway train, researchers are looking for the "brakes." Several molecular pathways have been identified as targets to stop or even reverse the damage:

  • Metabolic Housekeeping: Wenxiu He found that the drug semaglutide helps the heart by restoring mitophagy—the cell's ability to recycle damaged mitochondria—thereby reducing the inflammation that drives hypertrophy.
  • Signaling Silencers: Lang Jiang identified DUSP9 as a natural protective factor that silences the stress signals (ASK1) that tell heart cells to grow pathologically.
  • Pathway Blockers: Pan Li demonstrated that the SGLT2 inhibitor empagliflozin blocks the Wnt/β-catenin pathway, a major driver of heart thickening and fibrosis.

Beyond single-target drugs, traditional approaches are being re-examined through a modern lens. Yuanyuan Chen argues that multi-component formulas like QiShenYiQi pills may be more effective than single drugs because they simultaneously repair energy metabolism and neutralize oxidative stress, addressing the "multi-front war" the heart faces during remodeling.

Papers in this version

History & citationVersion 1 · 2026-10-04

Merged into another direction · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_mechanisms_of_pathological_cardiac_remod_692bc4f2,
  title = {Mechanisms of Pathological Cardiac Remodeling and Heart Failure},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/mechanisms-of-pathological-cardiac-remodeling-and-heart-failure/rdr_692bc4f20f794b90b35dd1567c27f269},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_mechanisms_of_pathological_cardiac_remod_692bc4f2_v1,
  title = {Mechanisms of Pathological Cardiac Remodeling and Heart Failure},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/mechanisms-of-pathological-cardiac-remodeling-and-heart-failure/rdr_692bc4f20f794b90b35dd1567c27f269/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}